Biologic Therapies for Immunoglobulin E-mediated Food Allergy and Eosinophilic Esophagitis.

Abstract

Immunoglobulin (Ig) E-mediated food allergy and eosinophilic esophagitis (EoE) are chronic, allergen-mediated disorders characterized by an aberrant TH2 immune response. The development and investigation of biologics for the treatment of IgE-mediated food allergy and eosinophilic esophagitis have provided further insight into the pathophysiology and management of these disorders. This article provides an overview of biologic therapies that are being investigated or have potential as treatments for IgE-mediated food allergy and eosinophilic esophagitis. Identification of EoE phenotypes that are responsive to biologics and investigation of biologics combined with other therapies may help elucidate a role for biologics in EoE.

• Authors: Iris M Otani, Kari C Nadeau
• Journal: Immunology and allergy clinics of North America (Immunol Allergy Clin North Am) Vol. 37 Issue 2 Pg. 369-396 (05 2017) ISSN: 1557-8607 [Electronic] United States
• PMID: 28366483 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2017 Elsevier Inc. All rights reserved.

Chemical References

• Allergens
• Antibodies, Anti-Idiotypic
• Antibodies, Monoclonal
• Biological Products
• Biomarkers
• Receptors, Interleukin-13
• Receptors, Interleukin-5
• anti-IgE antibodies
• Immunoglobulin E

Topics

• Allergens (immunology)
• Antibodies, Anti-Idiotypic (pharmacology, therapeutic use)
• Antibodies, Monoclonal (pharmacology, therapeutic use)
• Biological Products (pharmacology, therapeutic use)
• Biological Therapy (methods)
• Biomarkers
• Clinical Trials as Topic
• Eosinophilic Esophagitis (immunology, therapy)
• Food Hypersensitivity (immunology, therapy)
• Humans
• Immunoglobulin E (immunology)
• Molecular Targeted Therapy
• Receptors, Interleukin-13 (antagonists & inhibitors)
• Receptors, Interleukin-5 (antagonists & inhibitors)
• Treatment Outcome